—
Last 30 days
Recent Press Releases & News
Mesoblast Reports Ryoncil® Net Revenues of US$36M for the Quarter and US$115M for First Full Year of Product Launch
Mesoblast Limited (MESO) is a Great Momentum Stock: Should You Buy?
Mesoblast Completes Treatment Target in Phase 3 Back Pain Trial
Overview
52-week range
—
Avg surprise (last 0)
—
Avg reaction (last 0)
—
Earnings trends
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Fri Sep 4, 2026 | Jun/2026 | OTHER | — | — |
Implied volatility — last 90 days
No IV snapshots yet for MESO.
IV is captured twice daily (9:15 AM & 4:30 PM ET) for tickers with upcoming earnings. Comes online automatically once the next options refresh runs.